[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100612487":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":26,"locations":31,"responsibleParty":119,"collaborators":26,"id":123,"slug":124,"hasResults":125,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":125,"sex":131,"minAge":132,"maxAge":26,"enrollmentInfo":133,"targetDuration":26,"studyType":136,"phases":137,"briefSummary":139,"conditions":140,"keywords":145,"overallStatus":155,"whyStopped":26,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":165},{"fullName":5,"class":6},"Shiraz University of Medical Sciences","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention","ACTIVE_COMPARATOR","Consumption of 20 milligrams rosuvastatin daily",[13],"Drug: Rosuvastatin 20 mg\u002Fday",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo (placebo tablets similar to rosuvastatin)",[19],"Drug: Placebo tablets similar to rosuvastatin 20mg tablets",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Rosuvastatin 20 mg\u002Fday","Consumption of rosuvastatin 20mg tablets every day",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Placebo tablets similar to rosuvastatin 20mg tablets","consumption of placebo tablets similar to rosuvastatin 20mg",[15],[32,51,61,75,89,99,109],{"facility":33,"status":26,"city":34,"state":35,"zip":36,"country":37,"countryCode":38,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Motahari Breast Cancer Clinic","Shiraz","Fars","71344-1864","Iran","IR",{"type":40,"coordinates":41},"Point",[42,43],52.53113,29.61031,{"lat":43,"lon":42},[46],{"name":47,"role":48,"phone":26,"phoneExt":49,"email":50},"Armin Attar, Associate Professor","CONTACT","+98 71 3612 10","attar_armin@yahoo.com",{"facility":52,"status":26,"city":34,"state":35,"zip":26,"country":37,"countryCode":38,"cosmosGeoPoint":53,"geoPoint":55,"contacts":56},"Kowsar Hospital, Fars Heart Foundation",{"type":40,"coordinates":54},[42,43],{"lat":43,"lon":42},[57],{"name":58,"role":48,"phone":59,"phoneExt":26,"email":60},"Masoud Sayad","+98 71 3614 1000","masoud.sayad@yahoo.com",{"facility":62,"status":26,"city":63,"state":64,"zip":26,"country":37,"countryCode":38,"cosmosGeoPoint":65,"geoPoint":69,"contacts":70},"Toba Oncology Department, Mazandaran University of Medical Sciences","Sari","Mazandaran",{"type":40,"coordinates":66},[67,68],53.06009,36.56332,{"lat":68,"lon":67},[71],{"name":72,"role":48,"phone":73,"phoneExt":26,"email":74},"Maryam Nabati","+98 11 3304 4000","dr.mr.nabati@gmail.com",{"facility":76,"status":26,"city":77,"state":78,"zip":26,"country":37,"countryCode":38,"cosmosGeoPoint":79,"geoPoint":83,"contacts":84},"Modarres Hospital, Shahid Beheshti University of Medical Sciences","Tehran","Tehran Province",{"type":40,"coordinates":80},[81,82],51.42151,35.69439,{"lat":82,"lon":81},[85],{"name":86,"role":48,"phone":87,"phoneExt":26,"email":88},"Shabnam Kazemloo","+98 21 23515","kazemloo.shabnam@sbmu.ac.ir",{"facility":90,"status":26,"city":77,"state":78,"zip":26,"country":37,"countryCode":38,"cosmosGeoPoint":91,"geoPoint":93,"contacts":94},"Rajaee Hospital, Iran University of Medical Sciences",{"type":40,"coordinates":92},[81,82],{"lat":82,"lon":81},[95],{"name":96,"role":48,"phone":97,"phoneExt":26,"email":98},"Azin Alizadehasl","+98 21 3455 2001","alizadeasl@gmail.com",{"facility":100,"status":26,"city":77,"state":78,"zip":26,"country":37,"countryCode":38,"cosmosGeoPoint":101,"geoPoint":103,"contacts":104},"Sina Hospital, Tehran University of Medical Sciences",{"type":40,"coordinates":102},[81,82],{"lat":82,"lon":81},[105],{"name":106,"role":48,"phone":107,"phoneExt":26,"email":108},"Zahra Shajari","+98 21 6634 8587","adz.shajari@gmail.com",{"facility":110,"status":26,"city":77,"state":78,"zip":26,"country":37,"countryCode":38,"cosmosGeoPoint":111,"geoPoint":113,"contacts":114},"Taleghani Hospital, Shahid Beheshti University of Medical Sciences",{"type":40,"coordinates":112},[81,82],{"lat":82,"lon":81},[115],{"name":116,"role":48,"phone":117,"phoneExt":26,"email":118},"Alireza Farzaei","+98 21 2243 2566","alirezafarzaei@gmail.com",{"type":120,"investigatorFullName":121,"investigatorTitle":122,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Armin Attar","Prof. Armin Attar","100612487","phase-4-rosuvastatin-for-prevention-of-anthracycline-induced-cardiac-dysfunction-in-breast-cancer-patients-100612487",false,"NCT07254221","Rosuvastatin for Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients","Evaluation of Rosuvastatin Efficacy in Prevention of Anthracycline-induced Cardiac Dysfunction in Breast Cancer Patients After Chemotherapy","ROSUBREAST","Inclusion Criteria:\n\n* Female individuals with ≥18 years of age\n* Documented breast cancer diagnosis based on imaging and pathology findings\n* Scheduled to receive the first time anthracycline-based chemotherapy\n\nExclusion Criteria:\n\n* Baseline LVEF \\\u003C 50%\n* Prior Statin use or Statin use is indicated based on guidelines\n* history of congestive heart failure (CHF) or cardiomyopathy\n* Pregnancy or breastfeeding\n* Unable to provide informed consent\n* Unexplained persistent elevation of transaminases (\\>3 times upper limits of normal)\n* Concomitant use of oral cyclosporine\n* Metastatic invasion of cancer to other organs\n* Previous cycles of chemotherapy\n* Any contraindication for statin use","FEMALE","18 Years",{"count":134,"type":135},400,"ESTIMATED","INTERVENTIONAL",[138],"PHASE4","This study, called \"ROSUBREAST\", is a multicenter, double-blind, randomized clinical trial evaluating whether rosuvastatin (20 mg daily) can protect the heart in women with breast cancer receiving anthracycline-based chemotherapy. A total of 400 participants will be randomly assigned to receive either rosuvastatin or placebo for 12 months. The main goal is to determine whether rosuvastatin can prevent cancer treatment-related cardiac dysfunction (CTRCD), defined as a significant drop in heart pumping function. The study will also assess changes in cardiac strain, blood biomarkers, symptoms of heart failure, quality of life, and possible side effects.",[141,142,143,144],"Anthracycline-induced Cardiac Toxicity","Breast Cancer","Anthracycline Related Cardiotoxicity in Breast Cancer","Anthracycline-induced Cardiotoxicity",[146,147,148,149,150,151,152,153,154],"Breast cancer","rosuvastatin","statin therapy,","cancer-related treatment cardiac dysfunction","anthracycline induced cardiomyopathy","cardiac dysfunction","cardiotoxicity","chemotherapy","anthracycline","NOT_YET_RECRUITING","2025-12-03",{"date":158,"type":159},"2025-12-10","ACTUAL",{"date":161,"type":135},"2026-02-01",{"date":163,"type":135},"2028-04-21",{"name":5,"class":6},7]